Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, provides an overview of allogeneic chimeric antigen receptor (CAR) T-cell therapies in development. He describes ATA3219, a novel anti-CD19 CAR-T cell therapy developed for B-cell malignancies, as well as ATA2271, a mesothelin-targeted CAR-T immunotherapy for solid tumors. Tabelecleucel is an additional CAR-T cell therapy that treats Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) following hematopoietic cell or solid organ transplantation. This interview took place at Meeting on the Mesa 2021.

свернуть